PL2368913T3 - Przeciwciała ze zmodyfikowaną glikozylacją - Google Patents

Przeciwciała ze zmodyfikowaną glikozylacją

Info

Publication number
PL2368913T3
PL2368913T3 PL11163178T PL11163178T PL2368913T3 PL 2368913 T3 PL2368913 T3 PL 2368913T3 PL 11163178 T PL11163178 T PL 11163178T PL 11163178 T PL11163178 T PL 11163178T PL 2368913 T3 PL2368913 T3 PL 2368913T3
Authority
PL
Poland
Prior art keywords
glyco
engineered antibodies
engineered
antibodies
Prior art date
Application number
PL11163178T
Other languages
English (en)
Inventor
Manfred Schuster
Ralf Kircheis
Andreas Nechansky
Wolfgang Jost
Gilbert Gorr
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37635723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2368913(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Publication of PL2368913T3 publication Critical patent/PL2368913T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL11163178T 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją PL2368913T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06450095A EP1878747A1 (en) 2006-07-11 2006-07-11 Glyco-engineered antibodies
EP11163178.4A EP2368913B1 (en) 2006-07-11 2007-07-11 Glyco-engineered antibodies
EP07801422.2A EP2044121B1 (en) 2006-07-11 2007-07-11 Glyco-engineered antibodies

Publications (1)

Publication Number Publication Date
PL2368913T3 true PL2368913T3 (pl) 2015-05-29

Family

ID=37635723

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07801422T PL2044121T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją
PL11163178T PL2368913T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07801422T PL2044121T3 (pl) 2006-07-11 2007-07-11 Przeciwciała ze zmodyfikowaną glikozylacją

Country Status (12)

Country Link
US (2) US9051577B2 (pl)
EP (3) EP1878747A1 (pl)
JP (1) JP5424878B2 (pl)
KR (1) KR101565949B1 (pl)
CN (1) CN101495514A (pl)
CA (1) CA2657605C (pl)
DK (2) DK2368913T3 (pl)
ES (2) ES2529769T3 (pl)
IL (1) IL196022A (pl)
PL (2) PL2044121T3 (pl)
PT (1) PT2368913E (pl)
WO (1) WO2008006554A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8637435B2 (en) 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
JP5731827B2 (ja) 2008-03-03 2015-06-10 グライコフィ， インコーポレイテッド 下等真核生物中での組換えタンパク質の表面ディスプレイ
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
EP2433967A3 (en) 2009-03-16 2013-05-01 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
SG177764A1 (en) 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
CA2778552A1 (en) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
RU2012140429A (ru) 2010-02-24 2014-03-27 Мерк Шарп Энд Домэ Корп. Способ увеличения занятости участков n-ликозилирования на терапевтических гликопротеинах, продуцируемых в p pastoris
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
FR2980271B1 (fr) * 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013218017B2 (en) 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
ES2747920T3 (es) 2013-02-14 2020-03-12 Innate Pharma Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
WO2016146760A1 (en) 2015-03-17 2016-09-22 Greenovation Biotech Gmbh Glycosylated lysosomal proteins, method of production and uses
CA3001676C (en) 2015-10-12 2022-12-06 Aprogen Kic Inc. Anti-cd43 antibody and use thereof for cancer treatment
EP3430047A1 (en) 2016-03-15 2019-01-23 Innate Pharma Anti-mica antibodies
CN117717604A (zh) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
EP3529277A1 (en) 2016-10-21 2019-08-28 Innate Pharma Treatment with anti-kir3dl2 agents
KR102348638B1 (ko) * 2019-11-21 2022-01-11 (주)지플러스 생명과학 비푸코실화된 담배를 이용하여 생산한 항체 및 이의 용도
WO2021101351A2 (ko) * 2019-11-21 2021-05-27 (주)지플러스 생명과학 비푸코실화된 담배를 이용하여 생산한 항체 및 이의 용도
US20210322539A1 (en) * 2020-04-17 2021-10-21 Yigal Adir Cure to new viruses and other diseases that do not have current cure
WO2023127881A1 (ja) * 2021-12-28 2023-07-06 積水メディカル株式会社 検出方法及び検出試薬

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL91778A (en) * 1988-09-28 1994-10-07 Lilly Co Eli A method for reducing the heterogeneity of monoclonal antibodies
DK0528767T3 (da) 1991-08-21 2000-04-17 Novartis Ag antistofderivater
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
DE60044858D1 (de) * 1999-10-26 2010-09-30 Stichting Dienst Landbouwkundi Säugetierartige Glykosylierung in Pflanzen
DE10003573A1 (de) * 2000-01-27 2001-08-09 Mpb Cologne Gmbh Molecular Pla Hemmung von Kohlenhydrat-modifizierenden Enzymen in Wirtsorganismen
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
CL2003002461A1 (es) * 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2005000225A2 (en) * 2003-06-02 2005-01-06 University Of Oxford Production of rabies antibodies in plants
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
CA2563432A1 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
US7759464B2 (en) 2004-07-14 2010-07-20 Greenovation Biotech Gmbh N-glycosylated antibody
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
TW200637574A (en) 2005-01-13 2006-11-01 Genentech Inc Treatment method
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern

Also Published As

Publication number Publication date
EP2368913A2 (en) 2011-09-28
KR20090039756A (ko) 2009-04-22
JP2009542750A (ja) 2009-12-03
US10253098B2 (en) 2019-04-09
EP2368913B1 (en) 2014-12-24
EP2044121B1 (en) 2013-08-21
PT2368913E (pt) 2015-03-17
US20150284461A1 (en) 2015-10-08
ES2428875T3 (es) 2013-11-12
US9051577B2 (en) 2015-06-09
PL2044121T3 (pl) 2014-01-31
DK2044121T3 (da) 2013-10-07
KR101565949B1 (ko) 2015-11-06
IL196022A0 (en) 2011-08-01
WO2008006554A8 (en) 2008-03-13
CN101495514A (zh) 2009-07-29
EP2368913A3 (en) 2011-11-23
WO2008006554A3 (en) 2008-04-24
EP1878747A1 (en) 2008-01-16
WO2008006554A2 (en) 2008-01-17
DK2368913T3 (en) 2015-02-16
ES2529769T3 (es) 2015-02-25
IL196022A (en) 2015-01-29
CA2657605A1 (en) 2008-01-17
CA2657605C (en) 2018-11-06
EP2044121A2 (en) 2009-04-08
US20090291078A1 (en) 2009-11-26
JP5424878B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
IL196022A0 (en) Glyco-engineered antibodies
GB0708002D0 (en) Antibodies
DE602007002700D1 (en) Interventionsfreies frac-system
EP2078282A4 (en) ELECTRONIC COUPONS
DE602007014031D1 (en) Luftreifensatz
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
DE602007001601D1 (en) Glasuntersuchung
EP1983992A4 (en) 2-IMINO-BENZIMIDAZOLES
PT2011869E (pt) Novo anticorpo anti-cd98
DE602007003855D1 (en) Isothermer reaktor
GB0718737D0 (en) Antibodies
GB0615662D0 (en) Antibody
DE602007006989D1 (en) Spiropiperidinderivate
EP2084019A4 (en) PAINT SCRAPER
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2024567A4 (en) TONTAPETE
EP2007388A4 (en) OPIOPATHIEN
GB0713585D0 (en) Equivalent
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (en) UNDERWEAR
DE502007001126D1 (en) Eiten
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
AU4914P (en) CalflatGL Calothamnus quadrifidus